Institute of Pharmacy, Pt Ravishankar Shukla University, Raipur, India.
J Microencapsul. 2009 Jun;26(4):306-14. doi: 10.1080/02652040802319767. Epub 2008 Oct 20.
The present study aimed to develop an oral sustained release microparticulate system for acid labile enzyme-Serratiopeptidase. A 3(2) full factorial experiment was designed to study the effects of the external aqueous phase volume and stabilizer (Tween 80) concentration on the entrapment and size of Eudragit S100 microspheres prepared by a modified double emulsion solvent evaporation technique. The results of analysis of variance tests for both effects indicated that the test is significant. The effect of external aqueous phase volume was found to be higher on the entrapment efficiency of microspheres (SSY(1) = 1362.63; SSY(2) = 250.13), whereas Tween 80 produced a significant effect on size of microspheres (SSY(1) = 944.01; SSY(2) = 737.26). Scanning electron microscopy of microspheres demonstrated smooth surface spherical particles. The effect of formulation variables on the integrity of enzyme was confirmed by in vitro proteolytic activity. Microspheres having maximum drug encapsulation (81.32 ± 3.97) released 4-5% enzyme at pH 1.2 in 2 h. The release of enzyme from microspheres followed Higuchi kinetics (R(2) = 0.987). In phosphate buffer, microspheres showed an initial burst release of 25.65 ± 2.35% in 1 h with an additional 62.96 ± 4.09% release in the next 5 h. Thus, formulation optimization represents an economical approach for successful preparation of Eudragit S100 microspheres involving fewest numbers of experiments.
本研究旨在开发一种用于不稳定酶-糜蛋白酶的口服缓控释微粒系统。采用 3(2)完全析因实验设计,研究了外水相体积和稳定剂(吐温 80)浓度对采用改良的双乳化溶剂蒸发技术制备的 Eudragit S100 微球的包封率和粒径的影响。方差分析试验结果表明,两种因素均有显著影响。外水相体积对微球的包封率(SSY(1) = 1362.63; SSY(2) = 250.13)有较大影响,而吐温 80 对微球的粒径有显著影响(SSY(1) = 944.01; SSY(2) = 737.26)。微球的扫描电子显微镜显示出光滑的表面球形颗粒。通过体外蛋白水解活性证实了制剂变量对酶完整性的影响。载药量最大的微球(81.32 ± 3.97)在 pH 1.2 下 2 小时内释放 4-5%的酶。酶从微球中的释放遵循 Higuchi 动力学(R(2) = 0.987)。在磷酸盐缓冲液中,微球在 1 小时内初始突释 25.65 ± 2.35%,随后在接下来的 5 小时内再释放 62.96 ± 4.09%。因此,制剂优化代表了一种经济有效的方法,可成功制备涉及最少实验次数的 Eudragit S100 微球。